The purpose of this study is to determine whether nocturnal environmental control with Temperature controlled Laminar Airflow (TLA) is effective as add on treatment in patients with perennial allergic asthma.
Exposure to inhaled allergens is a pathogenetic factor in allergic asthma. However, physical, chemical and combined methods aiming to reduce airborne allergen levels have shown little or no effect in reducing asthma symptoms in people who are sensitive to perennial allergens.Aims and objectives: This study aims to investigate treatment with Temperature controled Laminar Airflow (TLA) with a very low particle concentration directed to the breathing zone in subjects with allergic asthma during night sleep. The hypothesis is that the decreased allergen exposure during the night will have an effect on quality of life and bronchial inflammation. Method: This is a multicentre, double blind, randomized 52 week parallel trial comparing active TLA treatment with Placebo. For ethical reasons the randomization is 2 to 1 for active and placebo treatment, respectively. A 2 weeks run-in period is inserted between inclusion and randomization, during which the patient shall get familiar with the use of the patient asthma diary and to adhere to the requirements of the study participation. First 12 weeks an unchanged maintenance medication will be kept and week 13-52 medication will be modified to obtain asthma control according to international guidelines (GINA). After inclusion, run-in, randomization and baseline measurements active/placebo treatment with AA will be implemented over 52 weeks.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
312
Nocturnal environmental control with Temperature controlled Laminar Airflow (TLA).
Placebo TLA (without filtration and TLA function)
Aarhus University Hospital
Aarhus, Denmark
Bispebjerg Hospital
Copenhagen, Denmark
Turku Allergy Centre
miniAQLQ (Mini Asthma Quality of Life Questionnaire, Appendix 1) and the corresponding paediatric PAQLQ score.
Time frame: Week -2, 0, 4, 12, 24, 36 and 52
FENO (Nitric Oxide in Exhaled Air)
Time frame: Week -2, 0, 4, 12, 24, 36 and 52
Lung function assessed by forced expiratory volume (FEV1), PEF (Expiratory peak flow) and FEF50 (Predicted Forced Expiratory Flow Rate at 50 Percent of Vital Capacity)
Time frame: Week -2, 0, 4, 12, 24, 36 and 52
Rhinitis symptoms assessed by questionnaire
Time frame: Week 0 and 52
RAST value and eosinophil count.
Time frame: Week 0 and 52
Asthma Control Test (ACT).
Time frame: Week -2, 0, 12, 24, 36 and 52
Resource consumption
Time frame: Week 0, 4, 12, 24, 36 and 52
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Turku, Finland
Ruhr University of Bochum
Bochum, Germany
University of München
München, Germany
University of Rostock
Rostock, Germany
Marien Hospital Wesel
Wesel, Germany
Ullevaal University Hospital
Oslo, Norway
St. Olavs Hospital
Trondheim, Norway
Ängelholm Hospital
Ängelholm, Sweden
...and 9 more locations